about
Abiraterone and increased survival in metastatic prostate cancerA phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab.Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerCarboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.Innovative approach for increasing physical activity among breast cancer survivors: protocol for Project MOVE, a quasi-experimental studyA Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia.Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.Acceptability and satisfaction of Project MOVE: a pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors.A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVEMolecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic diseaseInfluence of nurse navigation on wait times for breast cancer care in a Canadian regional cancer centerUtilizing RE-AIM to examine the translational potential of Project MOVE, a novel intervention for increasing physical activity levels in breast cancer survivorsOptimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialA Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
P50
Q29617512-3EAAC098-5320-4032-9ADF-C53D5EA95205Q33629947-46AD7600-D090-4EA5-9C10-06BCB013E78BQ35999644-CFA58F0A-3436-4C2F-A89A-97BA42345B13Q36033853-5BC80824-9AFC-4573-9F6C-D5FEDB64F187Q36136843-6AE1E4F6-663C-4B1B-B385-7E7C36DCF702Q36934323-DA48D7E6-7E23-4403-A7EA-DC9DB9708386Q36970765-BFEB2A13-7686-49C8-AA96-47D3371D1312Q37236896-E49EABB8-E09F-47F2-8282-9EAC048E8B88Q37514078-D737E4A8-AC30-469C-A255-89DB29977402Q40170696-845B9478-D5C5-4EFD-9316-B314DB9AD660Q42963970-7533CAE7-9B7E-4197-ABC9-9C53ADD5C21FQ43290574-FBAD0696-20A4-4804-865D-0F509C4C95EDQ46112080-877BEDA2-534E-42D5-891A-5D6F5B04D66AQ47282786-28748EFC-4FF4-4A00-BC66-B58B53D2AD38Q47614410-D8651365-D209-4044-8ABC-8D564165A5AFQ48045606-4C71B1FB-DD5B-4D7B-9A94-1E6C0FA3FEE1Q48097002-83712212-18D4-4BFF-857E-DECF0C972063Q51049137-5FC53CB7-D7F3-4C3F-A6A6-3B7398188B5AQ53706001-3656EA67-A86F-4928-8E75-C0C3ABBDA3FBQ54326161-1F5A84D2-A5C7-481C-9AE0-3405B098E462Q54364572-1E032B98-C5C3-4E47-8C11-42959C0CCAE9Q54572103-3AA95A8E-8824-4F63-98C3-80881D4ECD0DQ64110366-9D24043E-F479-449D-99D6-37957E0AC878Q80190894-9FEDBD4C-F2CD-4F52-BE2F-B9EB6D194422Q87800738-B6F215EF-3229-4188-B319-1F075C198894Q90637336-FE8AFA5C-DC18-4DE8-A797-C5117A43B2E9Q91285243-9971C137-1AC6-4CAE-A010-8003B67DDB1BQ91769958-1B3551E4-8DE5-4053-B106-29274D2399D8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Susan Ellard
@en
Susan Ellard
@nl
type
label
Susan Ellard
@en
Susan Ellard
@nl
prefLabel
Susan Ellard
@en
Susan Ellard
@nl
P31
P496
0000-0001-5757-9787